신약개발 소식, 해외 논문들

JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results

stayalive1 2020. 6. 8. 07:10

www.annalsofoncology.org/article/S0923-7534(19)49908-0/fulltext

 

Conclusions: JNJ-372 is a novel EGFR-cMET bispecific antibody with a manageable safety profile consistent with EGFR and cMET inhibition. Preliminary evidence suggests JNJ-372 can have activity in EGFR-driven NSCLC, including pts resistant to EGFR TKIs.

 

타그리소 내성에 대한 연구.

 

이 논문에 대한 우리나라 기사

www.medicaltimes.com/Users/News/NewsView.html?ID=1126834

 

 

저작자표시 비영리 변경금지

'신약개발 소식, 해외 논문들' 카테고리의 다른 글

FDA Clears IND for BBT-176 in Patients with EGFR-Mutant NSCLC  (0) 2020.06.09
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples  (0) 2020.06.09
Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study.  (0) 2020.06.08
Overview of EGFR-Mutated NSCLC and Pharmacology of EGFR TKIs  (0) 2020.06.08
Interim Analysis of Trastuzumab Deruxtecan in Patients With HER2-Mutated NSCLC  (0) 2020.06.08

'신약개발 소식, 해외 논문들'의 다른글

  • 현재글JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results

관련글

티스토리툴바